Thrombophilia screening in pregnancy

Obstetrical and Gynecological Survey

Volumn 60, Issue 6, 2005, Pages 394-404

  Jordaan, Dorothy Jo ^a   Schoon, Martinus Gerhardus ^a   Badenhorst, Philip Nel ^b  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; METHYLENETETRAHYDROFOLIC ACID; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

BLOOD CLOTTING; CESAREAN SECTION; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FETUS WASTAGE; FIBRINOLYSIS; GENE MUTATION; HUMAN; MATERNAL CARE; MORBIDITY; MORTALITY; OBESITY; PLACENTA; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; REVIEW; RISK FACTOR; SCREENING TEST; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS; FEMALE; FETAL DEATH; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 19744374727     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000165116.96026.4e     Document Type: Review

References (79)

1. Schoon M, Moodley J, Pattinson B, et al. Saving Mothers: Second Report on Confidential Enquiries Into Maternal Deaths in South Africa 1999-2001.
2. Hague WH, Dekker GA. Risk factors for thrombosis in pregnancy. Best Pract Res Clin Hematol 2000;16:197-210.
3. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003;109:73-81.
4. Lindqvist PG, Olofsson P, Dahlback B. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Obstet Gynecol 2002;100:332-336.
5. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002;99: 333-341.
6. Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta. Best Pract Res Clin Hematol 2003;16:183-195.
7. American College of Obstetricians and Gynecologists. Practice Bulletin no. 19: Thromboembolism in Pregnancy, August 2000.
8. Goddijn-Wessel TAW, Wouters MGAJ, v.d. Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-29.
9. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000;15:1830-1833.
10. Sikkema JM, Franx A, Bruinse HW, et al. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002; 23:337-342.
11. Arias F, Romero R, Joist H, et al. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998; 7:277-286.
12. Facchinetti F, Marozio L, Grandone E, et al. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica 2003;88:785-788.
13. Wiener-Megani Z, Benn-Shlomo I, Goldberg Y, et al. Resistance to activated protein C and the Leiden mutation: High prevalence in patients with abruptio placenta. Am J Obstet Gynecol 1998;179:1565-1567.
14. Greer IA. Thrombosis: maternal and fetal issues. Lancet 1999; 353:1258-1265.
15. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
16. Swaim LS, Gilstrap LC. Antithrombin III deficiency in pregnancy. Prim Care Update for OB/Gyns 1999;6:111-114.
17. Allaart CF, Poort SR, Reitsma PH, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-138.
18. Den Heijer M, Gerrits WBJ, Haak HL, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-885.
19. Auer J, Berent R, Eber B. Homocysteine: a novel risk factor in vascular disease. Coronary Health Care 2001;5:89-99.
20. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997;277: 1305-1307.
21. Cunningham FG, Gant NF, Leveno KJ, et al. Williams Obstetrics, 21st ed. New York: McGraw-Hill, 2001:1330-1332.
22. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003;101:1333-1344.
23. Geyzer S. Antiphospholipid syndrome. Dis Mon 2003;49:696-741.
24. Nimmo MC, Carter CJ. The antiphospholipid antibody syndrome. A riddle wrapped in a mystery inside an enigma. Clin Appl Immunol Rev 2003;4:125-140.
25. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832.
26. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. European Working Party on systemic lupus erythematosus. Medicine 1999;78:167-175.
27. Gebhardt GS, Hall DR. Inherited and acquired thrombophilias and poor pregnancy outcome: should we be treating with heparin? Curr Opin Obstet Gynecol 2003;15:501-506.
28. Sullivan PS, Dworkin DS, Jones JL, et al. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000;14:321-324.
29. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002;31:256-263.
30. Nicholson AC, Hajjar DP. Herpes viruses and thrombosis: activation of coagulation on the endothelium. Clin Chim Acta 1999;286:23-29.
31. Pryzdial ELG, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood 1994;84:3749-3757.
32. Powars DR, Rogers, Patch MJ, et al. Purpura fulminans in meningococcemia: association with acquired deficiencies of protein C and protein S. N Engl J Med 1987;317:571.
33. Manco-Johnson M, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with post-varicella purpura fulminans or thrombosis. J Pediatr 1996;128:319.
34. Weber M, Gerdsen F, Gutensohn K, et al. Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. Thromb Res 2002;107:325-328.
35. Mammen EF. Sticky platelet syndrome. Semin Thromb Hemost 1999;25:361-365.
36. Bick RL, Madden J, Heller K, et al. Recurrent miscarriage: causes, evaluation, and treatment. Medscape General Medicine 1999;1. Web site. Available at: http://www.medxcape-.com/viewarticle/408885. Accessed April 18, 2004.
37. Burgess L, Doubell A. Medical approach to deep vein thrombosis. The Specialist Forum 2003;3:40-46.
38. Rai R, Backos M, Elgaddal S, et al. Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod 2002;17:442-445.
39. Rai R, Shlebak A, Cohen H, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001;16:961-965.
40. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348: 913-916.
41. Many A, Elad R, Yaron Y, et al. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002;99:684-687.
42. Alonso A, Soto I, Urgelles MF, et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002;187:1337-1342.
43. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
44. Yamada H, Kato EH, Kobashi G, et al. Recurrent pregnancy loss: etiology of thrombophilia. Semin Thromb Hemost 2001; 27:121-129.
45. Rey E, Kahn SR, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908.
46. Sarig G, Younis JS, Hoffman R, et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002;77:342-347.
47. Carp H, Salomon O, Seidman D, et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002;17:1633-1637,
48. Foka ZJ, Lambropoulos AF, Saravelos H, et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000;15:458-462.
49. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489-493.
50. Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-739.
51. Rai R, Hadley E, Dave M, et al. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996;92:489-490.
52. Brenner B, Mandel H, Lanir Y, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551-554.
53. Grandone E, Margaglione M, Colaizzo S, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-824.
54. Arias F, Romero E, Joist H, et al. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions of the placenta. J Matern Fetal Med 1998; 7:277-286.
55. Blumenfeld Z, Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 1999;7:765-774.
56. Infante-Rivard C, David M, Gauthier R, et al. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991;325:1063-1066.
57. Vinatier D, Dufour P, Cosson M, et al. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2001;96:37-50.
58. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001;85:18-21.
59. Backos M, Rai R, Baxter N, et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102-107.
60. Ogunyemi D, Ku W, Arkel Y. The association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein a levels with obstetrical complications in pregnancy. Thromb Thrombolysis 2002;14:57-162.
61. Agorastos T, Karavida A, Lambropoulos A, et al. Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med 2002;12: 267-273.
62. Alferivic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? Eur J Obstet Gynecol Reprod Biol 2002;101:6-14.
63. Lindoff C, Ingemarsson I, Martinsson G, et al. Pre-eclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997;176:457-460.
64. Morrison ER, Miedzybrodzka ZH, Campbell F, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87:779-785.
65. Infante-Rivard C, Rivard GE, Wagner VYH, et al. Absence of association of thrombophilic polymorphism with intrauterine growth restriction. N Engl J Med 2002;347:19-25.
66. Alfirevic Z, Mousa HA, Martlew V, et al. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001;97:753-759.
67. Livingston JC, Barton JR, Park V, et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:153-157.
68. Van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of haemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999;180:1146-1150.
69. Rigo J Jr, Nagy B, Fintor L, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 2000;19:163-172.
70. Krauss T, Augustin HG, Osmers R, et al. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998;92:457-460.
71. McColl MD, Ramsy JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:183-1188.
72. Walker ID. Thrombophilia in pregnancy. A review. J Clin Pathol 2000;53:573-580.
73. Zotz RB, Gerhardt A, Scharf RE. Prediction, prevention and treatment of venous thromboembolic disease in pregnancy. A review. Semin Thromb Haemost 2003;29:143-154.
74. Greeves M. National Screening Committee: Workshop on screening for late onset genetic disorders-heritable thrombophilia. Available at: http://www.nelh.nhs.uk/screening/adult pps/throm rose report.pdf. Accessed December 13, 2000.
75. Mwelin T, Mundy L, Dekker G, et al. Antenatal screening for heritable thrombophilia. [Medical Services Advisory Committee web site.] Available at: http://www.health.gov.au/msac/pdfs/summaryref09b.pdf. Accessed August 2002.
76. Clark P, Twaddle S, Walker ID, et al. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002;359:1919-1920.
77. McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. A review. Br J Obstet Gynaecol 1999;106:756-766.
78. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med 2000;343:1439-1444.
79. Royal College of Obstetricians and Gynecologists Guideline. Thromboprophylaxis during pregnancy and after normal vaginal delivery. June 2003.